Abstract
Chronic granulomatous disease (CGD) is an inborn error of immunity associated with significant morbidity and mortality for which hematopoietic stem cell transplant (HSCT) is a definitive treatment. In a large single-center cohort, we examined the late survival (survival at 5 years post-HSCT) of all patients who underwent HSCT for CGD at the Children’s Hospital of Philadelphia (CHOP).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
